Clinical Trials Logo

Renal Vein Thrombosis clinical trials

View clinical trials related to Renal Vein Thrombosis.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT03778502 Recruiting - Clinical trials for Cerebral Vein Thrombosis

DOAC in Unusual Site Venous Thrombosis

DUST
Start date: October 1, 2019
Phase:
Study type: Observational [Patient Registry]

Unusual site venous thromboembolism (VTE) refers to thrombosis occurring in venous districts outside the veins of the lower extremities and the pulmonary arteries, and includes splanchnic vein thrombosis (SVT), cerebral vein thrombosis (CVT), retinal vein thrombosis, ovarian vein thrombosis, and renal vein thrombosis. The use of the novel direct oral anticoagulants (DOAC), thrombin or factor Xa-inhibitors (such as dabigatran, apixaban, edoxaban, rivaroxaban), in patients with unusual VTE in clinical practice is increasing. Through an international multicentre prospective registry, the investigators aim to evaluate the rationale for the use of the DOAC for the treatment of unusual site VTE and to assess the safety and effectiveness of this approach in real life clinical practice.